Please login to the form below

Use of biomarkers in marketing

Mark Assenti talks about utilisation of biomarkers in marketing is a trend that we have seen growing in 2014 and expect to hear even more about into 2015.


Prognosis biomarkers vs predictive biomarkers

The modern pharmaceutical market can be saturated with competing products, from bio-similar to same in-class to alternative MoA treatments. Standing out from the crowd can be tough; innovative and patient serving methods of differentiation are hard to come by.  

HCPs can struggle to find the right treatment for their patients and the cost of switching between products is often financially and emotionally high. Therefore, there is a need to personalise medicine for the individual; ensuring maximum efficacy, reducing conversion costs, as well as to be able to differentiate and position products within the treatment pathway.  

When we think of biomarkers, we usually imagine the detection of genetic disorders such as Huntington’s disease and Alzheimer’s; these are prognosis biomarkers. As we explore and understand more and more of the human genome, we are discovering more and more biomarkers, not just limited to disease diagnosis.  

Biomarkers are being used to determine a person’s genetic predisposition to respond well to certain treatments; these are predictive biomarkers. Investment and utilisation of this tool is a trend that we have seen growing in 2014 and predict to hear even more about into 2015.  

Let’s take an anonymous example to explore the power of this tool



A crowded market of biologics treating a chronic disease with very similar efficacy and safety evidence, all fighting for market leader position.   Detection of a predictive biomarker present in 60% of all patients shows, through retrospective analysis of clinical data, that efficacy levels in this patient segment are greatly increased for Product X. 95% of these patients achieve the primary endpoint compared to 70% of the general population (and market average) and continue to achieve results well after the ‘average patient’ has switched between treatments.   By segmenting patients in this way, pharma companies can:  

  • Identify patients suitable for 1st line treatment
  • Guarantee X% market share (dependant on biomarker prevalence within the population) 
  • Differentiate themselves from competitors
  • Offer a genuine service ‘around the pill’ with clear patient benefits   

The identification of a favourable predictive biomarker can not only optimise the life cycle of a product, but completely reshape marketing campaigns and pricing strategy. Commercial messaging developed around a patient subset with guaranteed superior results is hugely powerful, and can ignite key stakeholder engagement.  

Biomarkers influence regulatory positioning and can determine, to an extent, the placement of a product in the treatment pathway. Pricing can also be impacted; the inclusion of a ‘free’ biomarker diagnosis test is an option and some protection from price erosion in saturated markets may be possible.  

Biomarkers do have their limitations of course, their success and approval is hugely dependant on the evidence gathered and some marketers will fear removing potential customers by segmenting the market in this way. Despite this, pharma is becoming less reserved and beginning to see the true potential of this powerful scientific marketing tool. As knowledge in this area grows and certain pharma companies lead by example, we anticipate greater investment in this field and a trend towards the utilisation of biomarkers in brand strategies.


Mark Assenti is a Senior Associate Consultant at Blue Latitude. Mark began his career in the biosciences field, studying genetics at Cardiff University. His curiosity in this field lead him to discover a novel relationship between 2 bacteria native to the human gut.

What will be the Top 7 Trends in Pharma Marketing for 2015?
 Read our blog post here

Share this with your contacts: download this article

Downloads

  Use of biomarkers in marketing
PDF File: 391.6 KB

12th March 2015

Downloads

  Use of biomarkers in marketing
PDF File: 391.6 KB

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance treatment and improve patient and stakeholder outcomes.
Blue Latitude Health
The changing face of pharma in the precision era
Blue Latitude Health speaks to Nancy Brandt, a Senior Leader in Global Medical Information at a top 20 biopharma organisation. Here, she reveals what pharmaceutical companies need to do to prepare to bring precision medicines to market and how she is ensuring the patient is consulted every step of the way.
Blue Latitude Health
Creative problem solving, solved
Customer Experience Consultant Eimear Power explains how pharma teams can unlock their creativity and foster truly innovative ideas.
Blue Latitude Health
Three strategies for managing loss of exclusivity successfully
Claire Taylor, Senior Associate Consultant at Blue Latitude Health explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to make a more accurate treatment decision. Here we discuss the barriers, opportunities and potential outcomes of the precision medicine era in healthcare.
Blue Latitude Health
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the NHS is achieving this goal.
Blue Latitude Health